Litigation Details for Corcept Therapeutics, Inc v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2024)
✉ Email this page to a colleague
Corcept Therapeutics, Inc v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2024)
Docket | ⤷ Sign Up | Date Filed | 2024-01-11 |
Court | Court of Appeals for the Federal Circuit | Date Terminated | |
Cause | Assigned To | ||
Jury Demand | Referred To | ||
Patents | 10,195,214; 9,943,526 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Corcept Therapeutics, Inc v. Teva Pharmaceuticals USA, Inc.
Details for Corcept Therapeutics, Inc v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2024)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2024-04-22 | 10 | PATENT CLAIMS AT ISSUE Claims 10–13 of U.S. Patent No. 10,195,214: 10.…of nine method-of-treatment patents. By the time of trial, only two patents remained. Each requires co-administration… The two asserted patents share a specification. This brief cites the ’214 patent (Appx50–87). …Appx14–15. Corcept told the Patent Office during prosecution of the patents- in-suit that this language… obtains the asserted patents. That study led to the two asserted patents. Appx2580. According to | External link to document | |
2024-03-11 | 9 | infringe U.S. Patent Nos. 10,195,214 (“the ’214 patent”) and 10,842,800 (“the ’800 patent”) by marketing…States Patent No. 10,195,214 (“the ’214 Patent”) and claims 1, 6, 7, and 9 of United States Patent No.…in United States Patent No. 10,195,214 (“the ’214 Patent”) and United States Patent No. 10,842,800 (… PATENT CLAIMS AT ISSUE Claims 10-13 of U.S. Patent No. 10,195,214 10.…some of the patent claims at issue in this appeal (claims 10-13 of U.S. Patent No. 10,195,214). | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |